Diabetes in ischaemic stroke in a regional Australian hospital: uncharted territory.


Journal

Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952

Informations de publication

Date de publication:
04 2022
Historique:
revised: 05 09 2020
received: 08 07 2020
accepted: 06 09 2020
pubmed: 29 9 2020
medline: 16 4 2022
entrez: 28 9 2020
Statut: ppublish

Résumé

Stroke and diabetes mellitus (DM) are significant interrelated healthcare issues but there is a dearth of data on the prevalence of DM among Australia's regional stroke population. We aimed to determine the prevalence of DM in stroke patients at a large regional centre, including subanalyses on stroke subtypes, glycaemic control and renal function in ischaemic stroke (IS). We conducted a retrospective analysis of all patients (n = 323) with IS or transient ischaemic attack (TIA) admitted to Ballarat Base Hospital from January 2015 to December 2016. Demographic data, cardiovascular risk factors, aetiology/territory of IS, pre-morbid DM status, indicators of glycaemic control and renal impairment were recorded. DM was present in 28.5% of IS and TIA patients, including 4% being newly diagnosed. Among diabetic IS patients, 45.3% had poor glycaemic control (HbA1c ≥7.0%) while 16% had moderate to severe renal impairment (estimated glomerular filtration rate of <30). The majority of IS were partial anterior circulation stroke (53.4%) and cardioembolism was the commonest mechanism (43.5%). We found no significant association between DM and a specific stroke location or mechanism. Almost one-third of IS/TIA patients had DM, with a significant proportion showing poor glycaemic control. The DM prevalence in our cohort was comparable with reported rates from other developed countries. Although we found no association between DM and a particular stroke type or mechanism, it is likely a reflection of our cohort size. Our study demonstrated that DM, as a significant risk factor in IS, warrants early detection and better management strategies.

Sections du résumé

BACKGROUND
Stroke and diabetes mellitus (DM) are significant interrelated healthcare issues but there is a dearth of data on the prevalence of DM among Australia's regional stroke population.
AIMS
We aimed to determine the prevalence of DM in stroke patients at a large regional centre, including subanalyses on stroke subtypes, glycaemic control and renal function in ischaemic stroke (IS).
METHODS
We conducted a retrospective analysis of all patients (n = 323) with IS or transient ischaemic attack (TIA) admitted to Ballarat Base Hospital from January 2015 to December 2016. Demographic data, cardiovascular risk factors, aetiology/territory of IS, pre-morbid DM status, indicators of glycaemic control and renal impairment were recorded.
RESULTS
DM was present in 28.5% of IS and TIA patients, including 4% being newly diagnosed. Among diabetic IS patients, 45.3% had poor glycaemic control (HbA1c ≥7.0%) while 16% had moderate to severe renal impairment (estimated glomerular filtration rate of <30). The majority of IS were partial anterior circulation stroke (53.4%) and cardioembolism was the commonest mechanism (43.5%). We found no significant association between DM and a specific stroke location or mechanism.
CONCLUSIONS
Almost one-third of IS/TIA patients had DM, with a significant proportion showing poor glycaemic control. The DM prevalence in our cohort was comparable with reported rates from other developed countries. Although we found no association between DM and a particular stroke type or mechanism, it is likely a reflection of our cohort size. Our study demonstrated that DM, as a significant risk factor in IS, warrants early detection and better management strategies.

Identifiants

pubmed: 32985758
doi: 10.1111/imj.15073
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

574-580

Informations de copyright

© 2020 Royal Australasian College of Physicians.

Références

World Health Organization. Global Health Estimates 2016: Deaths by Cause, Age, Sex, by Country and by Region, 2000-2016. Geneva: World Health Organization; 2018.
Donkor ES. Stroke in the 21st Century: A snapshot of the burden, epidemiology, and quality of life. Stroke Res Treat. 2018;2018: 3238165.
Mukherjee D, Patil CG. Epidemiology and the global burden of stroke. World Neurosurg 2011; 76(Suppl): S85-90.
National Stroke Foundation. No Postcode Untouched: Stroke in Australia. Melbourne: National Stroke Foundation; 2017.
Deloitte Access Economics. The Economic Impact of Stroke in Australia. Melbourne: National Stroke Foundation; 2013.
Chen R, Ovbiagele B, Feng W. Diabetes and stroke: epidemiology, pathophysiology, pharmaceuticals and outcomes. Am J Med Sci 2016; 351: 380-6.
Tuttolomondo A, Pinto A, Salemi G, Di Raimondo D, Di Sciacca R, Fernandez P et al. Diabetic and non-diabetic subjects with ischemic stroke: differences, subtype distribution and outcome. Nutr Metab Cardiovasc Dis 2008; 18: 152-7.
Shou J, Zhou L, Zhu S, Zhang X. Diabetes is an independent risk factor for stroke recurrence in stroke patients: a meta-analysis. J Stroke Cerebrovasc Dis 2015; 24: 1961-8.
Lau LH, Lew J, Borschmann K, Thijs V, Ekinci EI. Prevalence of diabetes and its effects on stroke outcomes: a meta-analysis and literature review. J Diabetes Investig 2019; 10: 780-92.
Kang Z, Mrcp L, Nur W, Mmed N, Sahathevan R, Yong J et al. High prevalence of diabetes in stroke patients and its association with lacunar infarction. Neurol Asia 2015; 20: 121-7.
Australian Institute of Health and Welfare. Diabetes. Canberra: Australian Institute of Health and Welfare; 2019 [cited 2020 Apr 28]. Available from URL: https://www.aihw.gov.au/reports/diabetes/diabetes.
Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ, Culebras A et al. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013; 44: 2064-89.
Bamford J, Sandercock P, Dennis M, Warlow C, Burn J. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991; 337: 1521-6.
Adams H, Adams H, Bendixen B, Bendixen B, Kappelle L, Kappelle L et al. Classification of subtype of acute ischemic stroke. Stroke 2015; 23: 35-41.
American Diabetes Association. Standards of medical care in diabetes - 2019 abridged for primary care providers. Clin Diabetes 2019; 37(Suppl 1): 11-34.
Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 2013; 158: 825-30.
Fonville S, Zandbergen AAM, Vermeer SE, Dippel DWJ, Koudstaal PJ, Den Hertog HM. Prevalence of prediabetes and newly diagnosed diabetes in patients with a transient ischemic attack or stroke. Cerebrovasc Dis 2013; 36: 283-9.
Liu A, Carmichael KA, Schallom ME, Riley MJ, Klinkenberg WD. Detecting and managing diabetes mellitus and prediabetes in patients with acute stroke. Diabetes Educ 2015; 41: 592-8.
Huisa BN, Roy G, Kawano J, Schrader R. Glycosylated hemoglobin for diagnosis of prediabetes in acute ischemic stroke patients. J Stroke Cerebrovasc Dis 2013; 22: e564-7.
Sun Y, Toh MPHS. Impact of diabetes mellitus (DM) on the health-care utilization and clinical outcomes of patients with stroke in Singapore. Value Health 2009; 12: S101-5.
Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000; 321: 405-12.
Larsson SC, Scott RA, Traylor M, Langenberg CC, Markus HS. Type 2 diabetes, glucose, insulin, BMI, and ischemic stroke subtypes Mendelian randomization study. Neurology 2017; 89: 454-60.
Kiers L, Davis SM, Larkins R, Hopper J, Tress B, Rossiter SC et al. Stroke topography and outcome in relation to hyperglycaemia and diabetes. J Neurol Neurosurg Psychiatry 1992; 55: 263-70.
Scott DP, Greenfield JR, Bramah V, Alford J, Bennett C, Markus R. Challenges in secondary stroke prevention: prevalence of multiple metabolic risk factors, including abnormal glycaemia, in ischaemic stroke and transient ischaemic attack. Intern Med J 2010; 40: 275-80.
Lew J, Thijs V, Churilov L, Donnan G, Park W, Robbins R et al. Using routine HbA1c measurements in stroke and the associations of dysglycaemia with stroke outcomes. J Diabetes Complications 2018; 32: 1056-61.
Donnell MJO, Xavier D, Liu L, Zhang H, Chin SL, Rao-melacini P et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 2010; 376: 112-23.
Wong SWM, Mcgrath NM. Screening, prevalence and ethnic variation of diabetes mellitus in people with acute stroke and transient ischaemic attack: a cross-sectional study in New Zealand. N Z Med J 2016; 129: 62-6.
Read SH, McAllister DA, Colhoun HM, Farran B, Fischbacher C, Kerssens JJ et al. Incident ischaemic stroke and type 2 diabetes: trends in incidence and case fatality in Scotland 2004-2013. Diabet Med 2018; 35: 99-106.
Hjalmarsson C, Manhem K, Bokemark L, Andersson B. The role of prestroke glycemic control on severity and outcome of acute ischemic stroke. Stroke Res Treat 2014; 2014: 694569.
Sung J-Y, Chen C-I, Hsieh Y-C, Chen Y-R, Wu H-C, Chan L et al. Comparison of admission random glucose, fasting glucose, and glycated hemoglobin in predicting the neurological outcome of acute ischemic stroke: a retrospective study. PeerJ. 2017; 5: e2948.
Abboud H, Labreuche J, Arauz A, Bryer A, Lavados PG, Massaro A et al. Demographics, socio-economic characteristics, and risk factor prevalence in patients with non-cardioembolic ischaemic stroke in low- and middle-income countries: the OPTIC registry. Int J Stroke 2013; 8: 4-13.
Jia Q, Zheng H, Zhao X, Wang C, Liu G, Weng Y et al. Abnormal glucose regulation in patients with acute stroke across China: prevalence and baseline patient characteristics. Stroke 2012; 43: 650-7.
Sridharan SE, Unnikrishnan JP, Sukumaran S, Sylaja PN, Nayak SD, Sarma PS et al. Incidence, types, risk factors, and outcome of stroke in a developing country the Trivandrum stroke registry. Stroke 2009; 40: 1212-8.
Gofir A, Mulyono B, Sutarni S. Hyperglycemia as a prognosis predictor of length of stay and functional outcomes in patients with acute ischemic stroke. Int J Neurosci 2017; 127: 923-9.
Singh A, Brooks DD, Abrams TA, Poorak MD, Gunio D, Kandhal PK et al. Pre-stroke glycemia in patients with diabetes. Diabetes Metab Syndr Clin Res Rev 2017; 11: S891-3.
Lattanzi S, Bartolini M, Provinciali L, Silvestrini M. Glycosylated hemoglobin and functional outcome after acute ischemic stroke. J Stroke Cerebrovasc Dis 2016; 25: 1786-91.
Hu GC, Hsieh SF, Chen YM, Hsu HH, Hu YN, Chien KL. Relationship of initial glucose level and all-cause death in patients with ischaemic stroke: the roles of diabetes mellitus and glycated hemoglobin level. Eur J Neurol 2012; 19: 884-91.
Lei C, Wu B, Liu M, Chen Y. Association between hemoglobin A1C levels and clinical outcome in ischemic stroke patients with or without diabetes. J Clin Neurosci 2015; 22: 498-503.
Johnston KC, Bruno A, Pauls Q, Hall CE, Barrett KM, Barsan W et al. Intensive vs standard treatment of hyperglycemia and functional outcome in patients with acute ischemic stroke: the SHINE randomized clinical trial. JAMA 2019; 322: 326-35.
Zhai Z, Feng J. Early microalbuminuria as a clinical marker for acute cerebral small vessel infarction. Neurol Res 2019; 41: 151-5.
Li L, Li C. Microvascular complications of diabetes worsen long-term functional outcomes after acute ischemic stroke. J Int Med Res 2018; 46: 3030-41.
Jackson C, Sudlow C. Are lacunar strokes really different? A systematic review of differences in risk factor profiles between lacunar and nonlacunar infarcts. Stroke 2005; 36: 891-901.
Liu J, Rutten-Jacobs L, Liu M, Markus HS, Traylor M. Causal impact of type 2 diabetes mellitus on cerebral small vessel disease: a Mendelian randomization analysis. Stroke 2018; 49: 1325-31.

Auteurs

Chih-Chiang Hu (CC)

Faculty of Medicine, Ballarat Health Services, Ballarat, Victoria, Australia.

Ashlea Low (A)

Faculty of Medicine, Ballarat Health Services, Ballarat, Victoria, Australia.

Ellie O'Connor (E)

Faculty of Medicine, Ballarat Health Services, Ballarat, Victoria, Australia.

Pakeeran Siriratnam (P)

Faculty of Medicine, Ballarat Health Services, Ballarat, Victoria, Australia.

Casey Hair (C)

Faculty of Medicine, Ballarat Health Services, Ballarat, Victoria, Australia.

Thomas Kraemer (T)

Faculty of Medicine, Ballarat Health Services, Ballarat, Victoria, Australia.
School of Medicine, Deakin University, Geelong, Victoria, Australia.

Ramesh Sahathevan (R)

Faculty of Medicine, Ballarat Health Services, Ballarat, Victoria, Australia.
Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia.
Faculty of Medicine, Dentistry and Health Sciences, Florey Institute of Neuroscience and Mental Health, Melbourne, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH